OncoImmunology 14 477486 July 2012 G 2012 Landes Bioscience RESEARCH PAPER Humanizing murine IgG3 antiGD2 antibody m3F8 substantially improves antibodydependent cellmediated cytotoxicity retaining targeting vivo NaiKong V Cheung Hongfen Guo Jian Hu Dimiter V Tassev Irene Y Cheung Department Pediatrics Memorial SloanKettering Cancer Center New York NY USA Keywords chimeric humanized monoclonal antibodies MoAb antibodydependent cellmediated cytotoxicity ADCC complement mediated cytotoxicity CMC peripheral blood mononuclear cells PBMC polymorphonuclear leukocytes PMN Murine IgG3 antiGD2 antibody m3F8 shown antineuroblastoma activity Phase III studies antibody dependent cellmediated cytotoxicity ADCC played key role Humanization m3F8 circumvent human anti mouse antibody HAMA response enhance ADCC properties reduce dosing pain effect Chimeric 3F8 ch3F8 humanized 3F8 hu3F8IgG1 hu3F8IgG4 produced purified protein A affinity chromatography In vitro comparison m3F8 antiGD2 antibodies binding cytotoxicity crossreactivity assays In GD2 binding studies SPR ch3F8 hu3F8 maintained KD comparable m3F8 Unlike antiGD2 antibodies m3F8 ch3F8 hu3F8 substantially slower koff Similar m3F8 ch3F8 hu3F8 inhibited tumor cell growth vitro crossreactivity gangliosides comparable m3F8 Both peripheral blood mononuclear cell PBMCADCC polymorphonuclear leukocytes PMNADCC ch3F8 hu3F8 IgG1 potent m3F8 This superiority consistently observed ADCC assays irrespective donors NK92MItransfected human CD16 CD32 complement mediated cytotoxicity CMC reduced As expected hu3F8IgG4 near absent PBMCADCC CMC Hu3F8 m3F8 similar tumortonon tumor ratios biodistribution studies Antitumor effect neuroblastoma xenografts better hu3F8IgG1 m3F8 In conclusion humanizing m3F8 produced generation antiGD2 antibodies substantially potent ADCC vitro antitumor activity vivo By leveraging ADCC CMC clinically effective minimizing pain HAMA effects A Phase I trial hu3F8IgG1 ongoing Introduction Monoclonal antibody MoAb therapy accepted treatment modality cancers MoAb having received FDA approval solid tumors adults including colorectal breast cancer non small cell lung cancer squamous cell carcinoma melanoma12 This modality remained inadequately exploited treatment pediatric cancers Unlike chemo therapy radiation MoAb myelosuppressive geno toxic generally longterm toxicities These critical considerations young children More importantly MoAb effective metastatic cancer blood bone marrow bone typically high risk neuroblastoma NB As class agents pharmacokinetics toxicities human humanized IgG1 antibodies extensively studied In addition antibodies carry cytotoxic immunebased payloads radioisotopes toxins enzymes increasing options targeted therapy Correspondence NaiKong V Cheung Email cheungnmskccorg Submitted 022712 Accepted 030112 httpdxdoiorg104161onci19864 NB common extracranial solid tumor child hood In 50 cases curative strategies tackle soft tissue mass metastases bone marrow BM Dose intensive chemotherapy improves tumor resectability post surgical irradiation reduces risk relapse primary site 103 However BM disease evidenced histology metaiodobenzylguanidine MIBG scan persists forebodes lethal outcome45 In addition osteomedullary relapse common despite achieving near complete remission induction therapy Attempts treatment intensification met acute longterm effects grave concern young patients There scarcity promising new agents date targetpathwayspecific small molecules shown major clinical benefit patients NB promising leads continue accumulate6 With cure rate 30 toxicity limits Stage 4 patients diagnosed 18 mo age substantial room improvement7 wwwlandesbiosciencecom OncoImmunology 477 2012 Landes BioscienceDo distribute antibodydependent Ganglioside GD2 adhesion molecule abundant NB It ideal target MoAbbased therapy NB AntiGD2 cell efficient MoAb mediates highly mediated cytotoxicity ADCC NB presence human white cells It induces complement mediated cytotoxicity CMC NB cells lack decay accelerating factor CD558 homologous restriction factor CD599 Complement deposi tion NB cells enhances ADCC activation iC3b receptor neutrophils1011 available dose intensive myeloablative chemotherapy plus stem cell trans plant provided colony stimulating factors given12 Moreover use intensive chemotherapy standard care NB achieve clinical remission result prolonged lymphopenia immunosuppression13 patients likely reject murine chimeric MoAb14 At antibody families tested clinically 3F815 141816 Chimeric ch 1418 14G2a derived variable region murine MoAb 141817 They demonstrate ADCC CMC NB melanoma cells vivo1821 Based encouraging clinical responses Phase I studies ch1418 tested large Phase II studies consolidation therapy Stage 4 NB German NB90 NB97 studies For 166 patients 12 mo diagnosis event free survival similar patients receiving ch1418 compared patients maintenance chemotherapy overall survival improved rate BM relapse reduced22 In 2001 Childrens Oncology Group COG initiated randomized Phase III trial study efficacy com bination ch1418 GMCSF IL2 preventing NB relapse patients complete remission autologous stem cell transplant23 An interim analysis showed statistically significant improvement PFS OS 2 y24 vitro15 Among patients chemoresistant marrow disease despite doseintensive induction plus aggressive salvage regimen 80 achieved BM remission usually 1 2 cycles 5 days m3F8 plus GMCSF immunotherapy25 Given activity m3F8 chemoresistant marrow disease use expanded patients remission encourag ing results26 These favorable clinical outcomes children improved 3F8 given maintenance therapy 35 y highest recurrence risk However human anti mouse antibody HAMA limiting factor immune recovers following cessation chemotherapy One strategy reduce HAMA chimerize humanize 3F8 subject report Results Amino acid sequences chimeric3F8 humanized3F8 IgG1IgG4 The CDRs heavy light chains m3F8 grafted human IgG1 frameworks based homology human frameworks IGG HV333 IGKV3 15 respectively The amino acid sequences chimeric humanized heavy light chains shown Table 1 Table 2 respectively Additional constructs replacing heavy chain sequences m3F8 hu3F8IgG1 human IgG4 framework Table 3 transfected DG44 cells bluescript vectors Both chimeric humanized 3F8 purified standard protein A affinity chromatography On SDS gel chimeric humanized antibodies migrated IgG appropriate size heavy light chains HPLC eluted IgG 10 aggregate formation data shown By ELISA bound GD2 similar avidity m3F8 murine IgG3 MoAb specific GD2 induces cell death mediates efficient ADCC CMC NB Binding kinetics surface plasmon resonance SPR With antigen GD2 coated CM5 chips kinetics antibody Table 1 Amino acid sequences chimeric 3F8 heavy light chains CDR regions Ch3F8 heavy chaingamma1 QVQLKESGPGLVAPSQSLSITCTVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLSISKDNSKSQVFLKMNSLQIDDTAMYYCASRGGHYGYALDY WGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SIVMTQTPKFLLVSAGDRVTITCKASQSVSNDVTWYQQKAGQSPKLLIYSASNRYSGVPDRFTGSGYGTAFTFTISTVQAEDLAVYFCQQDYSSFGGGTKLEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Ch3F8 light chainkappa Table 2 Amino acid sequences humanized 3F8 heavy light chain CDR regions Hu3F8 heavy chaingamma1 QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDY WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Hu3F8 light chainkappa 478 OncoImmunology Volume 1 Issue 4 2012 Landes BioscienceDo distribute Table 3 Amino acid sequences chimeric humanized 3F8 heavy chain IgG4 subclass CDR regions Ch3F8 heavy chaingamma4 QVQLKESGPGLVAPSQSLSITCTVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLSISKDNSKSQVFLKMNSLQIDDTAMYYCASRGGHYGYALDY WGQGTSVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY GPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT ISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDY WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG PPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK Hu3F8 heavy chaingamma4 Figure 1 Comparative binding kinetics antiGD2 antibodies solid phase GD2 measured surface plasmon resonance Biacore T100 binding kon koff KD compared SPR Biacore T100 All engineered 3F8 including chimeric humanized IgG1 IgG4 comparable koff m3F8 better KD antiGD2 antibody 14G2a Fig 1 ME361 Table 4 The slow koff antibodies translated slower washoff antibodies reacted GD2 positive tumor cells LAN1 M14 washed multiple times wash buffer With wash remaining antibodies cell surface detected secondary FITClabeled goat intensity determined flow cytometry data shown antibody mean fluorescent antimouse Table 4 Binding kinetics chimeric humanized 3F8 surface plasmon resonance Antibody kon ch3F8IgG1 115E 05 hu3F8IgG1 919E 04 ch3F8IgG4 940E 04 hu3F8IgG4 118E 05 m3F8 14G2a ME361 174E 05 150E 05 121E 05 koff 145E 03 103E 03 128E 03 176E 03 874E 04 112E 02 279E 03 KD nM 13 3 11 1 14 2 15 1 5 1 77 8 19 7 Low crossreactivity gangliosides In cross reactivity studies hu3F8H1L1IgG1 similar profile ch3F8IgG1 m3F8 Table 5 There low level cross reactivity GD1b expressed percent OD ELISA relative OD solid phase GD2 There crossreactivity m3F8 hu3F8 14G2a human NCAM27 western blots SPR data shown Direct cytotoxicity When antibodies added neuroblastoma cells vitro induced direct cell death slowed vitro cell growth Upon assayed WST8 3d culture m3F8 hu3F8 similar potency EC50s compared Table 6 In contrast 14G2a 10fold weaker tumor cell killing Antibody potency ADCC CMC AntiGD2 antibodies compared ADCC assays PBMC PMN volunteers effectors LAN1 cells targets ADCC potencies antibodies computed ratio EC50 3F8EC50 MoAb Table 7 Relative m3F8 ch3F8 IgG1 hu3F8IgG1 300fold stronger PBMC ADCC 18fold stronger PMNADCC In addition maximal cytotoxicity achieved chimeric humanized 3F8 IgG1 subclass substantially consistently higher m3F8 14G2a irrespective PBMC ADCC PMNADCC wwwlandesbiosciencecom OncoImmunology 479 2012 Landes BioscienceDo distribute Table 5 Low crossreactivity gangliosides ELISA Mean SD Antibody ch3F8IgG1 hu3F8IgG1 ch3F8IgG4 hu3F8IgG4 m3F8 14G2a GM2GD2 0 0 0 0 0 0 GD1aGD2 02 09 0 0 0 0 0 GD1bGD2 88 08 45 07 61 22 31 16 41 10 0 09 GT1bGD2 GD3GD2 GQ1bGD2 0 0 0 0 0 0 02 09 0 0 0 0 0 0 0 0 0 0 0 In order examine capability MoAb ADCC individual FcR absence inhibitory FcR tested ADCC NK92MI cells carry human FcR cell surface Upon transfection human CD16 CD32 mediate efficient ADCC When effector cells LAN1 targets ch3F8IgG1 hu3F8IgG1 efficient 10fold m3F8 CD16ADCC CD32ADCC Hu3F8IgG4 subclass antibodies minimal PBMCADCC PMNADCC CD16ADCC CD32 activity compared m3F8 In human CMC ch3F8 hu3F8 14G2a efficient m3F8 A representative panel human NB cell lines tested cytotoxicity assays CD16ADCC CD32ADCC CMC Table 8 Even NB cell lines sensitive low GD2 antigen density SKNJC2 resistant Overall hu3F8 generally efficient m3F8 cytotoxicity Targeting human neuroblastoma xenografts Hu3F8IgG1 hu3F8IgG4 radiolabeled 131I They com parable immunoreactivity 4045 data shown Their biodistributions 48 h compared 131Im3F8 mice bearing sc LAN1 xenografts Tumor uptake measured IDgm comparable hu3F8IgG1 296 m3F8 286 nearly double hu3F8IgG4 Table 9 Tumor nontumor ratios comparable antibodies Treatment neuroblastoma xenografts 3F8 antibodies LAN1 widely studied human NB cell lines Even mouse effectors mouse complement generally suboptimal testing monoclonal antibodies established model vivo assays28 Mice xenografted established human NB LAN1 051 cm diameter treated Table 6 Direct cytotoxicity neuroblastoma cell line LAN1 presence antibodies Direct Cytotoxicity iv m3F8 hu3F8IgG1 twice weekly 4 weeks Tumor size weight survival monitored Hu3F8IgG1 100 mg dose inhibited tumor growth significantly p 005 compared m3F8 200 mg dose control mIgG3 100 mg dose At 20 mg dose hu3F8IgG1 effective Fig 2 Hu3F8IgG1 200 mg dose effective hu3F8 IgG1 100 mg dose data shown Survival mice receiving 100200 mg significantly longer p 0003 mice receiving PBS control m3F8 data shown Discussion AntiGD2 antibody proven therapy GD2postive NB29 Murine antibody 1418 derivatives 14G2a ch1418 provided benchmarks improving antiGD2 therapy We chose murine IgG3 antibody m3F8 clinical development 10fold slower koff compared 14G2a GD2 binding kinetics SPR Among patients chemo resistant metastatic NB bone marrow m3F8 plus GMCSF induced 80 complete remissions30 patients high risk metastatic NB remission m3F8 plus GMCSF associated 75 overall longterm survival26 However HAMA diminish effect murine antibody neutralizing ability bind antigen blocking direct effect antibody accelerating clearance antibody circulation Genetic engineering change murine human IgG frameworks reduce HAMA response Ch14183132 hu141833 derived VH VL 14G2a reduced immunogenicity patients We tested chimeric humanized forms 3F8 potential generation antiGD2 antibodies One criterion successful chimerization humanization preservation affinity genetic engineering It reassuring slow koff ch3F8 hu3F8 maintained Table 7 Antibody potency relative m3F8 ADCC CMC neuroblastoma LAN1 Antibody ch3F8IgG1 hu3F8IgG1 ch3F8IgG4 hu3F8IgG4 m3F8 14G2a EC50 ugml Antibody PBMC PMN NK92MICD16 NK92MICD32 CMC 45 12 51 12 64 18 31 00 19 02 471 ch3F8IgG1 hu3F8IgG1 ch3F8IgG4 hu3F8IgG4 m3F8 390 217 0 0 1 14G2a 003 18 19 1 4 1 1 24 12 0 0 1 4 13 15 3 1 1 2 064 040 001 003 1 012 480 OncoImmunology Volume 1 Issue 4 2012 Landes BioscienceDo distribute Table 8 Antibody potency relative m3F8 ADCC CMC seven neuroblastoma cell lines Antigen densitycell LAN1 499348 NMB7 932191 SKNLP 541522 BE1N 1080289 SKNMM 98613 SKNAS 33512 SKNJC2 16089 Antibody ch3F8IgG1 hu3F8IgG1 ch3F8IgG4 hu3F8IgG4 m3F8 14G2a ch3F8IgG1 hu3F8IgG1 ch3F8IgG4 hu3F8IgG4 m3F8 14G2a ch3F8IgG1 hu3F8IgG1 ch3F8IgG4 hu3F8IgG4 m3F8 14G2a 337 139 00 00 10 21 146 151 10 08 10 22 074 040 003 001 100 046 476 313 00 00 10 10 48 74 08 05 10 23 019 027 000 000 100 005 ADCCNK92CD16 471 357 00 00 10 13 ADCCNK92CD32 259 616 10 11 10 40 CMC 015 020 000 000 100 001 345 118 00 00 10 10 3939 14693 37 198 10 669 024 059 000 000 100 010 527 286 00 00 10 01 823 583 13 10 10 10 008 022 000 000 100 001 930 307 00 00 10 00 134 131 05 00 10 03 007 011 000 000 100 002 killing killing killing killing killing killing killing killing killing killing killing killing killing killing killing killing killing killing Table 9 Targeting 131Ilabeled hu3F8 antibodies LAN1 xenografts Biodistribution studies LAN1 N Organ Adrenal Bladder Blood Brain Femur Heart Kidney Large Int Liver Lung Muscle Skin Small Int Spine Spleen Stomach IDgm Tumor nontumor ratio m3F8 24 hu3F8IgG1 hu3F8IgG4 26 23 m3F8 24 hu3F8IgG1 hu3F8IgG4 26 23 Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 25 25 42 02 08 17 18 10 22 29 06 21 07 10 42 15 03 03 06 00 01 02 02 01 02 04 01 03 01 01 06 02 42 31 31 44 02 12 22 23 16 30 35 09 40 11 14 39 24 296 05 04 07 00 01 03 03 02 04 05 01 06 01 02 05 02 38 25 19 37 01 07 16 16 08 17 24 05 19 05 09 13 14 160 05 03 06 00 01 02 02 01 03 03 01 03 01 01 01 02 19 12 11 8 187 35 18 16 29 13 11 44 14 39 27 9 21 1 2 1 1 19 4 2 2 4 1 1 4 2 4 2 1 2 0 11 10 7 132 24 13 13 18 10 8 33 8 26 21 8 12 1 1 1 1 10 2 1 1 2 1 1 3 1 3 2 1 1 0 11 10 7 2 1 1 125 10 27 12 10 22 10 7 33 9 30 21 12 13 1 3 1 1 3 1 1 3 1 3 2 1 2 0 Tumor 286 wwwlandesbiosciencecom OncoImmunology 481 2012 Landes BioscienceDo distribute Figure 2 Treatment LAN1 subcutaneous neuroblastoma xenografts athymic nude mice Antibodies administered intravenously twice weekly total 8 doses m3F8 control mouse IgG3 effect tumor growth 100200 ug hu3F8IgG1 strongest antitumor effect p 005 student ttest day 21 treatment effect substantially 20 ug But importantly preservation enhancement vitro effector function vivo tumor targeting plus vivo therapeutic properties critical Both ch3F8IgG1 hu3F8IgG1 showed 200 fold efficient PBMC ADCC m3F8 PMNADCC 19fold In sharp contrast CMC ch3F8 hu3F8 substantially lower complement activating ability m3F8 This huge improvement ADCC desirable given recent evidence role antitumor effects MoAb patients Among lymphoma patients treated rituximab high affinity FcR2A FcR3A shown better response survival advantage34 While high affinity receptor FcR3A translated 10 improvement ADCC vitro35 overall response time progression improved 20034 When metastatic breast cancer treated Herceptin patients high affinity FcR3A better overall response 83 vs 35 p 003 longer progressionfree survival p 000536 For metastatic colorectal cancer treated cetuximab patients low affinity FcR2A FcR3A comparable hazard ratios patients mutated KRAS37 Using m3F8 patients high affinity FcR3A receptor myeloid cells shown better survival38 While binding affinity effector functions critical therapeutic applications crossreactivity pose unexpected toxicity issues We showed chimeric humanized forms 3F8 comparable crossreactivity patterns m3F8 ELISA assays purified gangliosides immunohistochemistry panel normal human tissues data shown Similar m3F8 engineered antibodies showed low level reactivity GD1b compared GD2 GD1b shown highly prevalent ganglioside NB tumors especially differentiated reti noids3940 This relevant 13cisretinoic acid routinely given patients undergoing immunotherapy high risk NB However antiGD1b antibodies asso ciated sensory ataxic neuropathies41 Nevertheless safety profile m3F8 permanent late sensory neuropathies 500 patients reassuring CMC unusually effective human NB42 low expression CD558 CD599 All antiGD2 antibodies mediate efficient CMC m3F8 particularly effective Yet studies rituximab suggested negative role complement activation downregulating ADCC43 In clinical studies higher activity complement component C1qA associated favorable response rituximab therapy44 For antiGD2 antibodies complement activation thought responsible pain effects45 FcCH2 domain mutated version hu1418K322A currently clinical trial Given considerations overdrive CMC prob ably desirable It reassuring increase ADCC efficiency ch3F8 hu3F8 accompanied increased CMC In summary hu3F8 retains slow koff allowing remain tumor cell surface longer periods It mediates potent ADCC vitro antitumor activity vivo maintaining excellent targeting efficiency compared m3F8 By leveraging ADCC CMC hu3F8 treatment potentially painful reduced incidence avoidance neutralizing antibodies Preliminary results Phase I clinical trial hu3F8 Clinicaltrialsgov NCT01419834 confirmed low immunogenicity hu3F8 highly favorable pharmacokinetics 482 OncoImmunology Volume 1 Issue 4 2012 Landes BioscienceDo distribute Materials Methods Cell culture human tissues Human NB cell line LAN1 provided Dr Robert Seeger Childrens Hospital Los Angeles NB1691 Dr Peter Houghton St Jude Childrens Research Hospital NK92MI obtained American Type Culture Collection ATCC All cell lines grown F10 RPMI 1640 medium supplemented 10 fetal bovine serum Hyclone South Logan UT 2 mM glutamine 100 Uml penicillin 100 mgml streptomycin 37C 5 CO2 incubator Normal tissues types obtained solid tumor Memorial SloanKettering Cancer Center MSKCC snapfrozen liquid nitrogen samples different histological Monoclonal antibodies m3F8 mouse IgG3 antibody kappa light chain15 antiNB activity previously described154647 It produced ascites purified affinity chromatography protein A GE Healthcare 90 pure SDSPAGE AntiGD2 hybridoma ME361 obtained ATCC 14G2a purchased BD Biosciences Construction hu3F8IgG1 hu3F8IgG4 ch3F8IgG1 ch3F8IgG4 antibody producer lines Based human homologs m3F8 CDR sequences heavy light chains m3F8 grafted human IgG1 framework optimized These hu3F8 genes synthesized CHO cells Blue Heron Biotechnology Genscript Using blue script vector Eureka CA heavy light chain genes hu3F8 transfected DG44 cells selected G418 InVitrogen CA Similarly mouse VH VL sequences grafted human IgG1 IgG4 frameworks ch3F8IgG1 ch3F8IgG4 recombinant antibodies From heavy chain light chain designs versions hu3F8 genes synthesized expressed DG44 cells Based vitro stability binding kinetics GD2 Biacore efficiency ADCC final heavy light chain sequences hu3F8IgG1 chosen Purification Hu3F8 ch3F8 Hu3F8 ch3F8 producer lines cultured Opticho serum free medium InVitrogen mature supernatant harvested Protein A affinity column preequilibrated 25 mM sodium citrate buffer 015 M NaCl pH 82 Bound hu3F8 eluted 01 M citric acidsodium citrate buffer pH 39 alkalinized 110 vv ratio 25 mM sodium citrate pH 85 It passed SartobindQ membrane concentrated 510 mgml 25 mM sodium citrate 015 M NaCl pH 82 Stability studies performed hu3F8IgG1 25 mM sodium citrate 015 M NaCl pH 82 vs PBS pH 74 presence absence 07 mgml Tween 80 Sigma Two micrograms proteins analyzed SDSPAGE nonreducing reducing conditions 415 Tris Glycine Ready Gel System BioRad Invitrogen SeeBlue Plus2 PreStained Standard protein molecular weight marker After electrophoresis gel stained PIERCEs GelCode Blue Stain Reagent The gel scanned Bio Rad FluorS MultiImager BioRad band intensity quantified Quantity One software BioRad Quantitation hu3F8 ch3F8 ELISA Microtiter plates coated GD2 20 ng 150 ml 05 BSA PBS diluent added plate 30 min ambient temperature block excess binding sites A purified batch hu3F8IgG1 construct standard curve starting 05 mgml followed 2fold dilutions 100 ml standard samples diluted 2fold added incubated 25 h 37C After washing plates PBS 100 ml goat anti humanIgG HL Jackson Research Laboratory diluted 13500 diluent added incubated 1 h 4C ELISA color reaction developed chromogen OPD Sigma substrate hydrogen peroxide 30 min room temperature RT dark The reaction stopped 5N H2S04 optical density OD read ELISA plate reader MRX Dynex 490 nm Based standard curve quantitation hu3F8 ch3F8 supernatants calculated microgramsmilliliters microgramsmilligrams protein In vitro binding kinetics Biacore T100 Biosensor Biacore AB GE Healthcare CM5 sensor chip Research grade related reagents purchased Biacore USA The ganglio sides GM1 ALEXIS Biochemicals AXXORA LLC GD2 Advanced ImmunoChemical In brief ganglio sides directly immobilized CM5 sensor chip hydrophobic interaction4849 Reference surface immobilized GM1 Active surface immobilized GD2 GM1 11 ratio Diluted mixture GD2 GM1 50 mgml injected 300 ml flow rate 15 mlmin 20 min Extensive washing followed 10 mM NaOH typically washes 20 ml flow rate 5 ml min stable baseline obtained Purified antiGD2 MoAb diluted HBSE buffer taining 250 mM NaCl varying concentrations 50 1600 nM prior analysis Samples 60 ml injected sensor surface flow rate 30 mlmin 2 min Following completion association phase dissociation monitored HBSE buffer containing 250 mM NaCl 300 sec flow rate At end cycle surface regener ated 50 ml 20 mM NaOH flow rate 50 mlmin 1 min 100 ml 4M MgCl2 flow rate 50 mlmin 2 min The biosensor curves obtained following injection samples immobilized GD2 subtracted control curves obtained samples injected immobi lized GM1 prior kinetics analysis The data analyzed bivalent analyte model default parameter setting rate constants Biacore T100 evaluation software apparent association rate constant kon dissociation rate constant koff equilibrium dissociation constant KD koffkon calculated ELISA crossreactivity gangliosides GD2 GM2 GD1a GD1b GT1b GD3 GQ1b coated polyvinyl microtiter plates 20 ng 90 ethanol Following air drying wells blocked 05 BSA PBS 150 ml 1 h room temperature Antibodies added triplicates 1 mgml 100 ml 05 BSA For background subtraction wells 1 antigen 2 wwwlandesbiosciencecom OncoImmunology 483 2012 Landes BioscienceDo distribute sample Following incubation 2 h 37C washing PBS HRPgoat antimouse IgG 11000 dilution mouse antibodies HRPgoat antihuman IgG 11000 dilution humanized antibodies Jackson Research Laboratory added After incubation 1 h 4C washing color reaction performed OD read ELISA plate reader 490 nm crossreactivity expressed maximal binding GD2 Direct cytotoxicity Antibodies tested direct effect tumor cell growth survival absence human serum human effector cells Tumor targets dissociated 2mM EDTA TrypsinEDTA washed plated 96well flat plates F10 12 cid1 103 35 cid1 104 After incubation 24 h 5 CO2 incubator 37C increasing concentrations antibodies F10 added Control wells received F10 After incubation 72 h 37C 5 CO2 WST8 reagent Cayman Chemical Co added incubated dark CO2 incubator 37C 26 h OD read 450 nm 690 nm ELISA plate reader WST8 assay validated direct cell counting Trypan Blue Sigma Beckman Coulter Counter Beckman Coulter Antibodydependent cellmediated cytotoxicity ADCC 51Chromium Release Target cells detached 2 mM EDTA Ca2 Mg2 free PBS washed F10 Antigen density estimated Quantum Simply Cellular anti Mouse IgG beads according manufacturers instructions Bangs Laboratories Inc For cytotoxicity assays 100 mCi 51Cr incubated 106 target cells final volume 250 ml incubated 1 h 37C gentle resuspension pellet 15 min intervals Cells washed resuspended 250 ml F10 incubated 30 min 37C After washing cells counted viability determined Trypan Blue quickly plated 96 Ubottom plates Peripheral blood normal volunteers collected heparinized tubes Blood mixed 3 dextranPBS kept room temperature 20 min sediment red cells White cells ficolled separated peripheral blood mononuclear polymorphonuclear PBMC leukocytes PMN PBMCADCC PMNADCC respect ively Cells washed F10 counted viability deter mined PBMCADCC presence 10 Uml IL2 PMNADCC 2 ngml GMCSF Antibodies diluted F10 1 mgml 10fold dilutions Plates incubated 37C 5 CO2 incubator 4 h Released 51Cr cells ADCC supernatant collected gamma counting Total release determined 10 sodium dodecyl sulfate release determined SDS background spontaneous F10 effectors An effectortarget ET ratio 501 generally Similarly ADCC assays performed NK92MI cells stably transfected human CD16 human CD32 Fc receptors Unlike PBMC PMN cytokines needed assay ET ratio generally kept 201 Biodistribution MoAb xenografted mice Female athymic nude mice purchased Harlan Spraque Dawley Inc All procedures performed accordance protocols approved Institutional Animal Care Use Committee institutional guidelines proper humane use animals research LAN1 tumor cells harvested resuspended Matrigel BD Biosciences Cells 2 10 cid1 106 implanted subcutaneously sc flank mice 01 ml volume 22gauge needles Tumors allowed grow size 200 mm3 initiating treatment Mice established tumors randomly separated treatment groups 100 mCi radioiodinated antibody mouse injected intravenously animals sacrificed usually 48 h organs removed counted gamma Packard Instruments Perkin Elmer These organs counter included skin liver spleen kidney adrenal stomach small intestine large intestine bladder femur muscle tumor heart lung spine brain Based mCi accumulated organ organ weight injected dose IDgm mouse calculated Tumor nontumor ratios IDgm calculated Therapy LAN1 neuroblastoma xenografts Studies com menced sc tumors reached 200 mg Mice randomly assigned treatment groups n 5 Antibodies administered intravenously iv twice week total doses Tumor volume body weight measured twice week Differences tumor sizes tested significance Students ttest Disclosure Potential Conflict Interest Hu3F8 patent filed Memorial SloanKettering Cancer Center NKC named inventor Acknowledgments Supported Band Parents Foundation Robert Steel Foundation We thank Yi Feng Hoa Tran excellent technical support References 1 Boyiadzis M Foon KA Approved monoclonal anti bodies cancer therapy Expert Opin Biol Ther 2008 httpdxdoiorg10 811518 151714712598881151 PMID18613766 2 Yan L Hsu K Beckman RA Antibodybased therapy solid tumors Cancer J 2008 1417883 PMID18536557 httpdxdoiorg101097PPO 0b013e318172d71a 3 Kushner BH Wolden S LaQuaglia MP Kramer K Verbel D Heller G et al Hyperfractionated lowdose radiotherapy highrisk neuroblastoma inten sive chemotherapy surgery J Clin Oncol 2001 19 28218 PMID11387353 4 Matthay KK Edeline V Lumbroso J Tanguy ML Asselain B Zucker JM et al Correlation early metastatic response 123Imetaiodobenzylguanidine scintigraphy overall eventfree response stage IV neuroblastoma J Clin Oncol survival 2003 21248691 PMID12829667 httpdxdoi org101200JCO200309122 Schmidt M Simon T Hero B Schicha H Berthold F The prognostic impact imaging 123ImIBG patients stage 4 neuroblastoma 1 year age highrisk treatment protocol results German Neuroblastoma Trial NB97 Eur J Cancer 2008 4415528 PMID18424129 httpdx doiorg101016jejca200803013 functional 5 6 Azarova AM Gautam G George RE Emerging importance ALK neuroblastoma Semin Cancer Biol 2011 2126775 PMID21945349 httpdxdoi org101016jsemcancer201109005 7 Pearson AD Pinkerton CR Lewis Imeson J Ellershaw C Machin D European Neuroblastoma Study Group Childrens Cancer Leukaemia Group CCLG United Kingdom Childrens Cancer Study Group Highdose rapid standard induction chemotherapy patients aged 1 year stage 4 neuroblastoma randomised trial Lancet Oncol 2008 924756 PMID18308250 httpdx doiorg101016S147020450870069X IJ 484 OncoImmunology Volume 1 Issue 4 2012 Landes BioscienceDo distribute 8 Cheung NK Walter EI SmithMensah WH Ratnoff WD Tykocinski ML Medof ME Decayaccelerating factor protects human tumor cells complement mediated cytotoxicity vitro J Clin Invest 1988 httpdxdoiorg10 8111228 1172JCI113426 PMID2450893 9 Chen S Caragine T Cheung NK Tomlinson S CD59 expressed tumor cell surface modulates decay accelerating factor expression enhances tumor growth rat model human neuroblastoma Cancer Res 2000 6030138 PMID10850450 10 Kushner BH Cheung NK Absolute requirement CD11CD18 adhesion molecules FcRII phosphatidylinositollinked FcRIII monoclonal antibodymediated neutrophil antihuman tumor cyto toxicity Blood 1992 79148490 PMID1347707 11 Metelitsa LS Gillies SD Super M Shimada H Reynolds CP Seeger RC Antidisialoganglioside granulocyte macrophagecolonystimulating factor fusion protein facilitates neutrophil antibodydependent cellular cytotoxicity depends FcgammaRII enhanced CD32 Mac1 CD11bCD18 effector cell adhesion azurophil granule exocy tosis Blood 2002 99416673 PMID12010822 httpdxdoiorg101182bloodV99114166 12 Mackall CL Tcell immunodeficiency following cyto toxic antineoplastic therapy review Stem Cells 2000 18108 PMID10661568 httpdxdoiorg101634 stemcells18110 13 Mackall CL Stein D Fleisher TA Brown MR Hakim FT Bare CV et al Prolonged CD4 depletion sequential autologous peripheral blood progenitor cell infusions children young adults Blood 2000 9675462 PMID10887145 cyclophosphamide 14 Kushner BH Cheung IY Kramer K Modak S Cheung inhibition NK Highdose humoral immune response murine monoclonal antibody 3F8 neuroblastoma patients broad impli cations immunotherapy Pediatr Blood Cancer 2007 484304 PMID16421906 httpdxdoiorg 101002pbc20765 15 Cheung NK Saarinen UM Neely JE Landmeier B Donovan D Coccia PF Monoclonal antibodies glycolipid antigen human neuroblastoma cells Cancer Res 1985 4526429 PMID2580625 16 Mujoo K Kipps TJ Yang HM Cheresh DA Wargalla U Sander DJ et al Functional properties effect growth suppression human neuroblastoma tumors isotype switch variants monoclonal antiganglioside GD2 antibody 1418 Cancer Res 1989 49285761 PMID2720646 17 Gillies SD Lo KM Wesolowski J Highlevel expres sion chimeric antibodies adapted cDNA variable region cassettes J Immunol Methods 1989 125191202 PMID2514231 httpdxdoiorg10 10160022175989900938 18 Barker E Mueller BM Handgretinger R Herter M Yu AL Reisfeld RA Effect chimeric anti ganglioside GD2 antibody cellmediated lysis human neuroblastoma cells Cancer Res 1991 51144 9 PMID1988079 19 Barker E Reisfeld RA A mechanism neutrophil mediated lysis human neuroblastoma cells Cancer Res 1993 533627 PMID8417829 20 Mueller BM Reisfeld RA Gillies SD Serum halflife tumor localization chimeric antibody deleted CH2 domain directed disialo ganglioside GD2 Proc Natl Acad Sci U S A 1990 8757025 httpdxdoiorg10 1073pnas87155702 PMID2198570 21 Mueller BM Romerdahl CA Gillies SD Reisfeld RA cytotoxicity Immunol J Enhancement antibodydependent chimeric antiGD2 antibody 1990 14413826 PMID2303711 22 Simon T Hero B Faldum A Handgretinger R Schrappe M Niethammer D et al Consolidation treatment chimeric antiGD2antibody ch1418 children older 1 year metastatic neuro blastoma J Clin Oncol 2004 22354957 PMID 15337804 httpdxdoiorg101200JCO200408 143 23 Gilman AL Ozkaynak MF Matthay KK Krailo M Yu AL Gan J et al Phase I study ch1418 granulocytemacrophage colonystimulating factor interleukin2 children neuroblastoma autologous bone marrow transplantation stemcell rescue report Childrens Oncology Group J Clin Oncol 2009 278591 PMID19047298 httpdxdoiorg101200JCO2006103564 24 Yu AL Gilman AL Ozkaynak MF London WB al Childrens Kreissman SG Chen HX Oncology Group AntiGD2 antibody GMCSF interleukin2 isotretinoin neuroblastoma N Engl J Med 2010 363132434 PMID20879881 httpdxdoiorg101056NEJMoa0911123 et GMCSF 25 Kushner B Kramer K Modak S Cheung NK Anti granulocytemacrophage GD2 anitbody 3F8 plus colony stimulating factor primary refractory neuroblastoma NB bone marrow BM Proc Am Soc Clin Oncol 2007 25526s 26 Cheung NK Kushner BH Kramer K Modak S S LaQuaglia M AntiGD2 Murine Wolden Monoclonal Antibody MoAb 3F8 Consolidation First CompleteVery Good Partial Remission High Risk Stage 4 Neuroblastoma NB Advances Neuroblastoma Research ANR Stockholm Sweden 2010 27 Patel K Rossell RJ Pemberton LF Cheung NKV Walsh FS Moore SE et al Monoclonal antibody 3F8 recognises neural cell adhesion molecule NCAM addition ganglioside GD2 Br J Cancer 1989 608616 PMID2481486 httpdxdoiorg101038 bjc1989380 28 Bergman I Basse PH Barmada MA Griffin JA vitro antibody Cheung NK Comparison targeted cytotoxicity mouse rat human effectors Cancer Immunol Immunother 2000 49259 66 httpdxdoiorg101007 s002620000120 PMID10941909 29 Yu A Gilman AL Ozkaynak MF London WB Kreissman S Chen HX et al A phase III randomized trial chimeric antiGD2 antibody ch1418 GMCSF IL2 immunotherapy following dose intensive chemotherapy highrisk neuroblastoma Childrens Oncology Group COG study ANBL0032 J Clin Oncol 2009 278591 PMID19047298 30 Kushner BH Kramer K Cheung NKV Phase II trial antiGD2 monoclonal antibody 3F8 granulocytemacrophage colonystimulating factor neuroblastoma J Clin Oncol 2001 19418994 PMID11709561 31 Yu AL UttenreutherFischer MM Huang CS Tsui CC Gillies SD Reisfeld RA et al Phase I trial humanmouse chimeric antidisialoganglioside mono clonal antibody ch1418 patients refractory neuroblastoma osteosarcoma J Clin Oncol 1998 16216980 PMID9626218 32 Ozkaynak MF Sondel PM Krailo MD Gan J Javorsky B Reisfeld RA et al Phase I study chimeric humanmurine antiganglioside GD2 monoclonal anti body ch1418 granulocytemacrophage colony stimulating factor children neuroblastoma immediately hematopoietic stemcell transplanta tion Childrens Cancer Group Study J Clin Oncol 2000 18407785 PMID11118469 33 Hank JA Gan J Ryu H Ostendorf A Stauder MC Sternberg A et al Immunogenicity hu1418IL2 immunocytokine molecule adults melanoma children neuroblastoma Clin Cancer Res 2009 15592330 PMID19737959 httpdxdoi org10115810780432CCR082963 polymorphisms 34 Weng WK Levy R Two immunoglobulin G frag ment C receptor independently predict response rituximab patients follicular lymphoma J Clin Oncol 2003 2139407 PMID httpdxdoiorg101200JCO200305 12975461 013 35 Niwa R Hatanaka S ShojiHosaka E Sakurada M Kobayashi Y Uehara A et al Enhancement antibodydependent cellular cytotoxicity lowfucose independent FcgammaRIIIa functional IgG1 Is polymorphism Clin Cancer Res 2004 10624855 PMID15448014 httpdxdoiorg1011581078 0432CCR040850 36 Musolino A Naldi N Bortesi B Pezzuolo D Capelletti M Missale G et al Immunoglobulin G fragment C receptor polymorphisms clinical efficacy trastu zumabbased therapy patients HER2neu positive metastatic breast cancer J Clin Oncol 2008 26178996 PMID18347005 httpdxdoiorg10 1200JCO2007148957 37 Bibeau F LopezCrapez E Di Fiore F Thezenas S Ychou M Blanchard F et al Impact FcgammaRIIa FcgammaRIIIa polymorphisms KRAS mutations clinical outcome patients metastatic colorectal cancer treated cetuximab plus irinote J Clin Oncol 2009 2711229 PMID19164213 httpdxdoiorg101200JCO2008180463 38 Cheung NK Sowers R Vickers AJ Cheung IY Kushner BH Gorlick R FCGR2A polymorphism correlated clinical outcome immunotherapy neuroblastoma antiGD2 antibody granu locyte macrophage colonystimulating factor J Clin Oncol 2006 24288590 PMID16682723 httpdx doiorg101200JCO2005046011 39 Hettmer S McCarter R Ladisch S Kaucic K Alterations neuroblastoma ganglioside synthesis induction GD1b synthase retinoic acid Br J Cancer 2004 9138997 PMID15187999 40 Hettmer S Malott C Woods W Ladisch S Kaucic K Biological stratification human neuroblastoma complex B pathway ganglioside expression Cancer Res 2003 6372706 PMID14612523 41 Gong Y Tagawa Y Lunn MP Laroy W HefferLauc M Li CY et al Localization major gangliosides PNS implications immune neuropathies Brain 2002 1252491506 PMID12390975 httpdxdoi org101093brainawf258 42 Saarinen UM Coccia PF Gerson S Pelley R Donovan D Cheung NKV In vitro eradication neuroblastoma NB cells monoclonal antibody Mab human complement C method purging autologous bone marrow BM Proc Am Assoc Cancer Res 1985 26291 43 Wang SY Veeramani S Racila E Cagley J Fritzinger DC Vogel CW et al Depletion C3 component complement enhances rituximab coated target cells activate human NK cells improves efficacy monoclonal antibody therapy vivo model Blood 2009 114532230 PMID 19805620 httpdxdoiorg101182blood200901 200469 ability wwwlandesbiosciencecom OncoImmunology 485 2012 Landes BioscienceDo distribute 44 Racila E Link BK Weng WK Witzig TE Ansell S Maurer MJ et al A polymorphism complement component C1qA correlates prolonged response following rituximab therapy follicular lymphoma Clin Cancer Res 2008 146697703 PMID18927313 httpdxdoiorg10115810780432CCR080745 45 Navid F Santana VM Barfield RC AntiGD2 antibody therapy GD2expressing tumors Curr Cancer Drug Targets 2010 102009 PMID20201786 httpdx doiorg102174156800910791054167 46 Cheung NK Modak S Lin Y Guo H Zanzonico P Chung J et al Singlechain Fvstreptavidin substan tially improved therapeutic index multistep targeting directed disialoganglioside GD2 J Nucl Med 2004 4586777 PMID15136638 47 Modak S Kramer K Gultekin SH Guo HF Cheung NK Monoclonal antibody 8H9 targets novel cell surface antigen expressed wide spectrum human solid tumors Cancer Res 2001 61404854 PMID 11358824 48 Catimel B Scott AM Lee FT Hanai N Ritter G Welt S et al Direct immobilization gangliosides gold carboxymethyldextran sensor surfaces hydrophobic interaction applications antibody characterization Glycobiology 1998 892738 PMID9675226 http dxdoiorg101093glycob89927 49 Hu J Huang X Ling CC Bundle DR Cheung NK Reducing epitope spread affinity maturation antiganglioside GD2 antibody J Immunol 2009 183574855 PMID19812201 httpdxdoiorg10 4049jimmunol0901409 486 OncoImmunology Volume 1 Issue 4 2012 Landes BioscienceDo distribute